Dynavax $DVAX, in its regulatory filing, reported that FDA review team has asked for more information about its Biologics License Application (BLA) seeking approval of HEPLISAV-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)]. The company, however, dispelled fears by saying that a probe from the review team was in line with its expectations. The drug-maker is cooperating with the review team to resolve all remaining questions in order to make sure the completion of its review by the scheduled action date of December 15.